To complement these efforts by our group and to develop a different class of Stat3 inhibitor for use in cancer treatment with the potential for oral administration, we determined if recent information obtained regarding the structural requirements of Stat3 SH2/pY-peptide binding [23], [27] could be exploited to develop a small-molecular inhibitor of Stat3. This evidence concerns the gene STAT3 and cancer.